Syngene International Ltd

AI

Syngene International Ltd

₹ 435 -1.41%
17 Nov 2:28 p.m.
About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Key Points

Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers. It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.

  • Market Cap ₹ 17,560 Cr.
  • Current Price ₹ 435
  • High / Low ₹ 679 / 344
  • Stock P/E 66.0
  • Book Value ₹ 120
  • Dividend Yield 0.28 %
  • ROCE 9.99 %
  • ROE 7.78 %
  • Face Value ₹ 10.0

Pros

Cons

  • Stock is trading at 3.67 times its book value
  • The company has delivered a poor sales growth of 11.4% over past five years.
  • Company has a low return on equity of 10.2% over last 3 years.
  • Dividend payout has been low at 12.0% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
910 854 917 790 891 944 1,018 874 911 917 1,036 736 833
656 622 600 620 646 660 674 668 711 708 733 645 685
Operating Profit 254 232 317 170 245 284 344 206 200 209 303 91 147
OPM % 28% 27% 35% 22% 27% 30% 34% 24% 22% 23% 29% 12% 18%
14 26 16 50 16 18 19 18 15 -55 16 12 21
Interest 13 11 13 12 13 12 16 12 13 12 12 10 10
Depreciation 105 108 111 107 111 109 106 111 116 114 112 112 112
Profit before tax 151 138 209 101 137 181 240 101 85 28 196 -19 47
Tax % 23% 19% 10% 25% 23% 27% 24% 14% 21% 47% 25% -53% 31%
116 112 189 76 106 131 183 87 67 15 148 -9 32
EPS in Rs 2.90 2.77 4.69 1.88 2.64 3.26 4.55 2.15 1.67 0.37 3.67 -0.22 0.80
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
860 1,107 1,201 1,423 1,826 2,012 2,184 2,604 3,193 3,489 3,642 3,739 3,522
579 727 816 949 1,289 1,394 1,507 1,861 2,251 2,472 2,598 2,817 2,772
Operating Profit 281 380 385 474 537 618 678 743 942 1,017 1,045 921 751
OPM % 33% 34% 32% 33% 29% 31% 31% 29% 30% 29% 29% 25% 21%
12 6 94 53 75 153 94 75 63 77 101 -9 -6
Interest 8 8 18 23 32 35 28 24 45 47 53 49 44
Depreciation 81 97 114 131 164 219 274 310 366 426 433 453 449
Profit before tax 204 281 346 372 415 517 469 484 594 621 660 411 252
Tax % 14% 14% 17% 18% 20% 20% 14% 18% 22% 18% 25% 23%
175 241 287 305 332 412 405 396 464 510 496 317 186
EPS in Rs 4.38 6.02 7.18 7.64 8.29 10.30 10.12 9.88 11.57 12.69 12.33 7.86 4.62
Dividend Payout % 239% 8% 7% 7% 3% 0% 0% 10% 11% 10% 10% 16%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: 5%
TTM: -6%
Compounded Profit Growth
10 Years: %
5 Years: 0%
3 Years: -8%
TTM: -43%
Stock Price CAGR
10 Years: 5%
5 Years: -6%
3 Years: -16%
1 Year: -32%
Return on Equity
10 Years: %
5 Years: 11%
3 Years: 10%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 199 200 200 200 200 400 400 401 401 402 402 403 404
Reserves 646 825 1,213 1,520 1,768 1,776 2,421 2,897 3,217 3,856 4,324 4,436 4,455
155 891 806 787 813 773 893 1,022 815 555 578 458 507
422 440 555 681 922 1,214 1,169 1,245 1,398 1,339 1,491 1,757 1,292
Total Liabilities 1,422 2,356 2,775 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 7,055 6,658
503 580 810 1,030 1,377 2,020 2,201 2,393 2,667 2,850 2,802 3,000 2,880
CWIP 105 237 175 155 274 234 237 346 177 838 1,266 1,046 1,141
Investments 146 277 540 158 716 776 702 1,034 918 548 647 741 610
667 1,262 1,249 1,846 1,337 1,133 1,743 1,790 2,069 1,916 2,081 2,268 2,028
Total Assets 1,422 2,356 2,775 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 7,055 6,658

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
18 308 398 446 630 677 701 581 824 1,042 1,168 915
16 -753 -470 -349 -646 -424 -629 -611 -653 -494 -744 -839
-10 716 -81 -79 -72 -226 58 -31 -342 -551 -142 -215
Net Cash Flow 24 272 -153 18 -88 28 130 -62 -172 -4 281 -138
Free Cash Flow -178 16 92 82 47 34 255 105 305 553 398 547
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 22% 92% 123% 111% 135% 127% 116% 92% 102% 115% 123% 107%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 76 61 60 68 68 72 79 71 61 46 53 50
Inventory Days 59 44 37 82 30 18 41 87 141 94 60 56
Days Payable 106 87 116 195 154 156 167 113 109 100 136 138
Cash Conversion Cycle 29 18 -19 -44 -56 -66 -47 45 92 40 -23 -32
Working Capital Days -64 -65 -44 -48 -103 -172 -66 -43 -14 -27 -51 -68
ROCE % 23% 20% 18% 17% 17% 14% 13% 15% 15% 13% 10%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Active Clients
clients

Log in to view insights

Please log in to see hidden values.

Login
R&D and Manufacturing Infrastructure
Million sq. ft.
Number of Scientists
scientists
Total Headcount
employees
Patents Held with Clients
patents
PhDs in Workforce
PhDs
Client and Regulator Audits
audits
Research Services Share of Revenue
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
54.79% 54.79% 54.72% 54.72% 52.74% 52.74% 52.68% 52.68% 52.68% 52.68% 52.59% 52.59%
21.20% 20.92% 20.64% 20.72% 20.65% 19.47% 16.51% 16.31% 14.96% 13.91% 11.82% 10.13%
14.63% 15.80% 16.78% 17.49% 19.52% 21.50% 24.05% 24.62% 25.83% 26.44% 28.01% 29.31%
9.07% 8.18% 7.44% 6.74% 6.79% 5.99% 6.45% 6.08% 6.22% 6.69% 7.15% 7.55%
0.32% 0.31% 0.43% 0.34% 0.29% 0.29% 0.31% 0.30% 0.29% 0.29% 0.43% 0.41%
No. of Shareholders 1,21,8801,15,8501,20,0181,07,3381,28,8061,25,0901,42,3101,36,0611,31,7501,35,6051,42,2771,34,008

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls